Hormonal
African-American prepubertal children exhibit significantly lower insulin clearance and higher insulin secretion compared to American White children, resulting in hyperinsulinemia that is not merely a compensatory response to insulin resistance but involves an upregulated beta-cell function.
This research highlights that metabolic differences exist between racial groups, specifically regarding how insulin is cleared and secreted. For African-American children, these physiological differences may predispose them to higher insulin levels even with similar body composition to white peers. While this is a descriptive finding, it underscores the importance of monitoring metabolic health markers early. Dietary patterns, particularly the ratio of fat to carbohydrates, correlate with these metabolic rates, suggesting that nutritional interventions could potentially modulate these risks.
In conclusion, the hyperinsulinemia observed in AA children is due to both lower insulin clearance and higher insulin secretion compared with their white peers. The quantitative relationship between insulin secretion and sensitivity is upregulated in AA children. This suggests that increased insulin secretion in AA children is not merely a compensatory response to lower insulin sensitivity.
Why this rating
Controlled clinical study with matched body composition, though limited to a specific demographic (prepubertal children).
Source
Hyperinsulinemia in African-American Children
Silva Arslanian et al. · Diabetes · 2002
DOI 10.2337/diabetes.51.10.3014
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →